We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

46 hedge funds and large institutions have $434M invested in Entrada Therapeutics in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

81.29% more ownership

Funds ownership: 0% → 81.29% (+81%)

Holders
46
Holders Change
+46
Holders Change %
–
% of All Funds
0.71%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
46
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$114M
2
MAM
MPM Asset Management
Massachusetts
+$107M
3
5VM
5AM Venture Management
California
+$107M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$75.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$49M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$80.5M +$114M +4,704,419 New
MAM
2
MPM Asset Management
Massachusetts
$75.8M +$107M +4,425,784 New
5VM
3
5AM Venture Management
California
$75.5M +$107M +4,408,379 New
Wellington Management Group
4
Wellington Management Group
Massachusetts
$52.8M +$75.5M +3,114,006 New
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$34.6M +$49M +2,020,637 New
RG
6
Redmile Group
California
$33.5M +$47.4M +1,954,420 New
SG
7
StepStone Group
California
$13M +$18.5M +761,277 New
TCM
8
TCG Crossover Management
California
$11.4M +$16.1M +663,694 New
7IH
9
72 Investment Holdings
Connecticut
$8.71M +$12.3M +509,024 New
Goldman Sachs
10
Goldman Sachs
New York
$7.63M +$10.8M +445,455 New
BlackRock
11
BlackRock
New York
$7.61M +$10.8M +444,426 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$7.27M +$10.3M +424,952 New
Fidelity Investments
13
Fidelity Investments
Massachusetts
$4.89M +$6.93M +285,800 New
APM
14
Avidity Partners Management
Texas
$4.37M +$6.18M +255,000 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.78M +$3.93M +162,187 New
Citadel Advisors
16
Citadel Advisors
Florida
$1.86M +$2.64M +108,794 New
SCM
17
Suvretta Capital Management
New York
$1.81M +$2.57M +106,000 New
MCM
18
Moore Capital Management
New York
$1.8M +$2.55M +105,000 New
State Street
19
State Street
Massachusetts
$1.39M +$1.97M +81,119 New
Northern Trust
20
Northern Trust
Illinois
$1.36M +$1.93M +79,483 New
Charles Schwab
21
Charles Schwab
California
$1.1M +$1.55M +64,019 New
TD Asset Management
22
TD Asset Management
Ontario, Canada
$987K +$1.4M +57,675 New
Millennium Management
23
Millennium Management
New York
$796K +$1.13M +46,504 New
Bank of America
24
Bank of America
North Carolina
$391K +$554K +22,842 New
GCM
25
Ghisallo Capital Management
Massachusetts
$257K +$364K +15,000 New
1
2

TRDA Hedge Fund Activity: Q4 2021 in Review

46 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2021, worth a combined $434M.

Buyers outnumbered sellers: 46 funds opened new TRDA positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $114M.

  • 46 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $434M of Entrada Therapeutics stock for Q4 2021.
  • 46 funds opened new Entrada Therapeutics positions in Q4 2021 and 0 closed out, a net change of +46 holders.
  • The largest Entrada Therapeutics buyer in Q4 2021 was Baker Bros. Advisors, an estimated $114M added.

Based on aggregated 13F filings for Q4 2021.